100 related articles for article (PubMed ID: 7589598)
21. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of predictive markers for patients with advanced colorectal cancer.
Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
[TBL] [Abstract][Full Text] [Related]
23. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
Hartmann JT; Köhne CH; Schmoll HJ; Daikeler T; Kanz L; Bokemeyer C
Oncology; 1998; 55(4):320-5. PubMed ID: 9663421
[TBL] [Abstract][Full Text] [Related]
24. Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
Rougier P; Nordlinger B
Ann Oncol; 1993; 4 Suppl 2():21-8. PubMed ID: 8353101
[TBL] [Abstract][Full Text] [Related]
25. 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer.
Falcone A; Allegrini G; Masi G; Lencioni M; Pfanner E; Brunetti I; Danesi R; Bocci G; Del Tacca M; Conte P
Oncology; 2001; 61(1):28-35. PubMed ID: 11474245
[TBL] [Abstract][Full Text] [Related]
26. Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Okabe S; Ishikawa T; Tanami H; Kuwabara H; Fukahara T; Udagawa M; Ootsukasa S; Arai T; Maruyama S; Murase N; Yamashita H; Iwai T
J Med Dent Sci; 2002 Jun; 49(2):77-84. PubMed ID: 12627817
[TBL] [Abstract][Full Text] [Related]
27. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
28. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
[TBL] [Abstract][Full Text] [Related]
29. Double-blind randomised trial comparing 5-fluorouracil plus leucovorin to placebo for metastatic colorectal carcinoma.
Madden M; Goldberg P; Geddes C; Van der Merwe L
Colorectal Dis; 2005 Sep; 7(5):507-12. PubMed ID: 16108890
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
31. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
Kulig J; Popiela T; Richter P; Klek S
Acta Chir Belg; 2007 Jun; 107(3):297-301. PubMed ID: 17685257
[TBL] [Abstract][Full Text] [Related]
33. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.
Matsumoto S; Imaeda Y; Umemoto S; Kobayashi K; Suzuki H; Okamoto T
Br J Cancer; 2002 Jan; 86(2):161-7. PubMed ID: 11870500
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients.
Nobile MT; Canobbio L; Sobrero A; Galligioni E; Vidili MG; Fassio T; Lo Re G; Rubagotti A; Sertoli MR; Rosso R
Adv Exp Med Biol; 1988; 244():213-8. PubMed ID: 3073656
[No Abstract] [Full Text] [Related]
36. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
Lévi F; Misset JL; Brienza S; Adam R; Metzger G; Itzakhi M; Caussanel JP; Kunstlinger F; Lecouturier S; Descorps-Declère A
Cancer; 1992 Feb; 69(4):893-900. PubMed ID: 1735081
[TBL] [Abstract][Full Text] [Related]
37. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
Punt CJ; Nagy A; Douillard JY; Figer A; Skovsgaard T; Monson J; Barone C; Fountzilas G; Riess H; Moylan E; Jones D; Dethling J; Colman J; Coward L; MacGregor S
Lancet; 2002 Aug; 360(9334):671-7. PubMed ID: 12241873
[TBL] [Abstract][Full Text] [Related]
38. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
[TBL] [Abstract][Full Text] [Related]
40. Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma.
Kang EJ; Choi YJ; Kim JS; Kim ST; Park KH; Choi IK; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2010 Dec; 6(4):286-91. PubMed ID: 21114778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
